Ozempic maker: We sold health when people wanted weight loss
Why now
Thesis: Novo's marketing misstep may cede weight-loss market share to Eli Lilly.
Catalyst to watch: Eli Lilly's next earnings or pipeline update.
Main risk: Novo corrects strategy, limiting Lilly's gain.
Why it matters
Novo Nordisk's strategic misstep in marketing GLP-1 drugs may affect competitive dynamics in the weight-loss drug market, potentially benefiting Eli Lilly's market share.
Details
Novo Nordisk invented the GLP-1 category, told the world that weight loss was the least important thing its drugs did, and then watched a competitor take market share by promising a bigger number. Mike Doustdar became president and CEO of Novo Nordisk in August 2025, after 34 years at the company t
Related assets & topics
Novo Nordisk · NVOSources
- youtube · 2026-09-07 15:00 UTC